# Liraglutide Around Cardiac Surgery: What Four Randomized Trials Did Not Establish > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/liraglutide-cardiac-surgery-randomized-trials-meta-analysis/ > **Published:** 2026-09-05T17:35:56-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:36-04:00 > **Clinical Summary:** liraglutide cardiac surgery meta-analysis: A meta-analysis of four randomized cardiac-surgery trials found no clear liraglutide effect on 30-day mortality, o... --- CED Clinical Relevance #80 GLP-1 Clinical Evidence Report A new peer-reviewed systematic review pooled four randomized trials and reports clinically important null and imprecise outcomes. Full text was unavailable, so every claim is confined to the PubMed abstract. Clinical Insight | CED Clinic A meta-analysis of four randomized cardiac-surgery trials found no clear liraglutide effect on 30-day mortality, overall postoperative complications, cardiac adverse events, hypoglycemia, or nausea and vomiting. Wide confidence intervals and only 446 randomized patients limit certainty. The pooled abstract did not establish better or worse rates for the reported clinical and safety outcomes. It also did not provide enough information to assess the article’s glycemic efficacy claims, so those results are not summarized here. Clinical decisions require patient-specific review. GLP-1LiraglutideCardiac SurgeryMeta-analysisSafety AudiencePatients, caregivers, clinicians, and cannabis-science readers interested in perioperative glucose management in cardiac surgery Primary Topicperioperative liraglutide in adults undergoing cardiac surgery Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42693519/) A meta-analysis of four randomized cardiac-surgery trials found no clear liraglutide effect on 30-day mortality, overall postoperative complications, cardiac adverse events, hypoglycemia, or nausea and vomiting. Wide confidence intervals and only 446 randomized patients limit certainty. What This Study Teaches Us Across seven reports from four trials involving 446 randomized patients, pooled estimates did not show statistically clear differences in 30-day mortality, any postoperative complication, cardiac adverse events, hypoglycemia, or postoperative nausea and vomiting. Several confidence intervals were wide enough to include important benefit or harm. Why This Matters Perioperative hyperglycemia matters, but so do hypoglycemia and postoperative complications. The synthesis asks whether liraglutide improves that balance in cardiac surgery. Its abstract supports caution: selected safety and clinical outcomes were not clearly different, and the available sample was too small for confident conclusions about uncommon or severe events. Study SnapshotStudy TypeSystematic review and meta-analysis of randomized controlled trialsEvidence BaseSeven reports from four trials, with 446 randomized adults undergoing cardiac surgeryInterventionPerioperative subcutaneous liraglutideComparatorsPlacebo or insulin-based usual careMortality30-day mortality: 1 of 161 versus 3 of 160; RR 0.42, 95% CI 0.06 to 2.81Any Postoperative ComplicationRR 0.92, 95% CI 0.74 to 1.14Cardiac Adverse EventsRR 1.08, 95% CI 0.83 to 1.40Hypoglycemia8 of 165 versus 9 of 166; RR 0.85, 95% CI 0.34 to 2.13Nausea and VomitingRR 3.01, 95% CI 0.26 to 35.27PublishedSeptember 4, 2026PMID / DOI42693519 / 10.1097/CRD.0000000000001465Sourcing BoundaryFull text was unavailable; the PubMed abstract did not report the glycemic efficacy estimates named in the article title Clinical Bottom Line The pooled abstract did not establish better or worse rates for the reported clinical and safety outcomes. It also did not provide enough information to assess the article’s glycemic efficacy claims, so those results are not summarized here. Four Trials Are a Narrow Evidence Base The review included 446 randomized patients across four trials reported in seven publications. Randomized evidence is valuable, but this total is limited for mortality, uncommon complications, and subgroup questions. Mortality Remained Highly Uncertain There was one death among 161 liraglutide participants and three among 160 controls within 30 days. The risk ratio confidence interval ranged from substantial benefit to substantial harm, so the estimate does not establish a mortality effect. Overall Complications Were Not Clearly Different The pooled risk ratio for any postoperative complication was 0.92, with a 95% confidence interval from 0.74 to 1.14. That interval includes no difference and does not justify a claim that liraglutide prevents postoperative complications. Safety Estimates Need More Precision Cardiac adverse events and hypoglycemia were not statistically different between groups in the reported analyses. The nausea and vomiting estimate was exceptionally imprecise, with a confidence interval from 0.26 to 35.27, leaving clinically important uncertainty. The Abstract Does Not Report Glycemic Estimates Although glycemic efficacy appears in the article title, the available PubMed abstract does not provide pooled glucose or insulin-use estimates. Without accessible full text, those outcomes cannot be responsibly reconstructed or summarized from the title alone. How Strong Is This Evidence? The authors searched four major databases, used duplicate screening and extraction, applied Cochrane Risk of Bias 2, graded certainty with GRADE, and restricted the evidence synthesis to randomized trials. Where This Paper Deserves Skepticism Only four trials and 446 patients were available. Event counts were low, several confidence intervals were wide, comparator strategies varied, and the accessible abstract omitted the glycemic efficacy estimates named in the title. What This Paper Does Not Show The abstract does not establish lower mortality, fewer overall complications, fewer cardiac adverse events, less hypoglycemia, or more postoperative nausea and vomiting. It also does not provide enough data here to claim improved perioperative glucose control or reduced insulin requirements. How This Fits With the Broader Clinical Conversation Perioperative GLP-1 decisions require separate consideration of chronic indications, fasting and aspiration concerns, glucose control, insulin protocols, gastrointestinal symptoms, and surgical context. A meta-analysis can organize small randomized trials, but pooling cannot replace missing event numbers, complete outcome reporting, or adequately powered contemporary trials. Dr. Caplan’s Take *This synthesis is most useful as a map of uncertainty. The reported clinical and safety outcomes were not clearly different, while several estimates were too imprecise to exclude meaningful benefit or harm.* *I would not use the abstract alone to start, stop, hold, or continue liraglutide around surgery. Those decisions belong with the surgical, anesthesia, diabetes, and prescribing teams using current patient-specific guidance.* What a Careful Reader Should Take Away Four small randomized trials did not establish clear differences in the reported postoperative outcomes, and inaccessible glycemic results prevent a complete efficacy interpretation. Evidence Interpretation Guide Table of Contents - [How to Interpret This Perioperative Liraglutide In Adults Undergoing Cardiac Surgery Evidence Without Overstating It](#How_to_Interpret_This_Perioperative_Liraglutide_In_Adults_Undergoing_Cardiac_Surgery_Evidence_Without_Overstating_It)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame) - [Eight Clinical Ways to Read This Evidence](#Eight_Clinical_Ways_to_Read_This_Evidence)[A Meta-analysis Is Not a Perioperative Instruction](#A_Meta-analysis_Is_Not_a_Perioperative_Instruction) - [The Reported Endpoints Are Mostly Inconclusive](#The_Reported_Endpoints_Are_Mostly_Inconclusive) - [Four Deaths Cannot Settle Survival](#Four_Deaths_Cannot_Settle_Survival) - [A Broad Composite Can Hide Different Outcomes](#A_Broad_Composite_Can_Hide_Different_Outcomes) - [Hypoglycemia Was Not Clearly Reduced](#Hypoglycemia_Was_Not_Clearly_Reduced) - [The Nausea Estimate Is Exceptionally Uncertain](#The_Nausea_Estimate_Is_Exceptionally_Uncertain) - [The Abstract Omits Glycemic Efficacy Results](#The_Abstract_Omits_Glycemic_Efficacy_Results) - [Perioperative Trials Need More Than Surrogate Control](#Perioperative_Trials_Need_More_Than_Surrogate_Control) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This Perioperative Liraglutide In Adults Undergoing Cardiac Surgery Evidence Without Overstating It A useful evidence report should let the signal breathe without inflating it. The right question is not whether the paper is positive or negative, but what kind of decision it can responsibly support. ### A Four-Step Reading Frame **Evidence type**Start by identifying whether the paper is a randomized trial, review, meta-analysis, observational study, or protocol. **Population**Ask whether the studied population matches the patient or clinical scenario involving perioperative glucose management in cardiac surgery. **Outcome meaning**Look at what actually changed, how it was measured, and whether the change would matter in daily life. **Safety and uncertainty**Read limitations and adverse effects as part of the result, not as a footnote. The Research Question What does the current evidence suggest about perioperative liraglutide in adults undergoing cardiac surgery? The Patient Question Does this mean I should use cannabinoids for perioperative glucose management in cardiac surgery? The Bottom Line The evidence can inform a careful conversation, but it does not replace individualized clinical care. CED Perspective Lens ## Eight Clinical Ways to Read This Evidence Distinct implications for patients, clinicians, methods, safety, and future research Lens OverviewEach viewpoint stays within the verified paper and separates the measured finding from decisions the evidence cannot make. #### A Meta-analysis Is Not a Perioperative Instruction The review combined four randomized trials of liraglutide around cardiac surgery. Its reported abstract outcomes did not show clear differences in mortality, overall complications, cardiac adverse events, hypoglycemia, or nausea and vomiting. That does not tell an individual patient whether to hold or continue medication before surgery. Aspiration risk, gastrointestinal symptoms, diabetes control, fasting instructions, drug indication, procedure type, and anesthesia planning require a coordinated decision from the treating teams. Lens takeawayUse this evidence for discussion, not for changing perioperative medication without the care team. #### The Reported Endpoints Are Mostly Inconclusive The pooled risk ratios for overall complications, cardiac adverse events, and hypoglycemia included the null. Mortality events were rare, and the confidence interval was too wide to establish benefit or harm across ordinary cardiac-surgery settings. Clinicians should avoid converting non-significance into equivalence or safety proof. The evidence supports uncertainty about these outcomes in a small randomized literature. Perioperative decisions still need contemporary guidance, glucose-management plans, and patient-specific assessment rather than a pooled estimate alone. Lens takeawayTreat null statistical tests as inconclusive when precision and event counts are limited. #### Four Deaths Cannot Settle Survival The abstract reports one death among 161 liraglutide participants and three among 160 controls within 30 days. The pooled risk ratio was 0.42, but its 95 percent confidence interval ran from 0.06 to 2.81. That interval includes a large possible reduction, no effect, and a substantial possible increase. The numerical imbalance is not proof of protection. Much larger trials or high-quality pooled data are needed before survival can influence routine perioperative liraglutide decisions. Lens takeawayLow event counts make the mortality estimate unstable and clinically nondefinitive. #### A Broad Composite Can Hide Different Outcomes Any postoperative complication occurred in 68 of 129 liraglutide participants and 76 of 132 controls, producing a risk ratio of 0.92 with a 95 percent confidence interval from 0.74 to 1.14 in the pooled analysis. The result does not establish prevention of complications. A broad composite can also combine events with different severity and mechanisms. Without accessible full text, this report cannot responsibly reconstruct every component, timing definition, or individual trial-level contribution. Lens takeawayDo not overread a broad composite whose pooled estimate includes no difference. #### Hypoglycemia Was Not Clearly Reduced Hypoglycemia occurred in 8 of 165 liraglutide participants and 9 of 166 controls. The risk ratio of 0.85 had a 95 percent confidence interval from 0.34 to 2.13, leaving the direction unresolved. The estimate is compatible with benefit, no effect, or harm. Although glucose-dependent pharmacology provides a rationale for study, mechanism does not substitute for outcome precision. Glucose monitoring and rescue protocols remain necessary in cardiac surgery for every treatment group. Lens takeawayThe pooled hypoglycemia result is too imprecise to promise a safer glucose strategy. #### The Nausea Estimate Is Exceptionally Uncertain For postoperative nausea and vomiting, the pooled risk ratio was 3.01, but the 95 percent confidence interval ranged from 0.26 to 35.27. Such a wide interval signals sparse data and a notably unstable estimate. This result neither proves an increase nor provides reassurance. Gastrointestinal symptoms matter in perioperative care because they may affect fasting, aspiration assessment, hydration, and recovery. Patient-specific symptom review remains more actionable than this imprecise pooled number. Lens takeawayRecognize the possible gastrointestinal signal while acknowledging that its magnitude is unresolved. #### The Abstract Omits Glycemic Efficacy Results The article title names glycemic efficacy, but the complete PubMed abstract does not report pooled glucose levels, insulin requirements, time in range, or other glycemic estimates. Full text was not available through PMC or an open-access location. Those missing results cannot be inferred from the title, pharmacology, or prior trials. This report therefore limits itself to the outcomes explicitly available and identifies the omission. Complete appraisal should await access to the full article. Lens takeawayWhen key results are unavailable, transparent omission is safer than reconstructed certainty. #### Perioperative Trials Need More Than Surrogate Control Future trials should be large enough for clinically important complications and should report glucose control, insulin exposure, hypoglycemia, aspiration-related events, gastrointestinal symptoms, length of stay, and patient-centered recovery outcomes with consistent definitions across participating surgical centers. They should also distinguish chronic users from newly initiated perioperative treatment and account for procedure type, diabetes status, dose, fasting plan, and comparator insulin protocol. Better harmonization and complete reporting would make future pooling more informative. Lens takeawayBuild larger, consistently reported trials that connect glucose management to meaningful surgical outcomes. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Liraglutide+Around+Cardiac+Surgery%3A+What+Four+Randomized+Trials+Did+Not+Establish&url=https%3A%2F%2Fcedclinic.com%2Fliraglutide-cardiac-surgery-randomized-trials-meta-analysis%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fliraglutide-cardiac-surgery-randomized-trials-meta-analysis%2F) [BlueSky](https://bsky.app/intent/compose?text=Liraglutide+Around+Cardiac+Surgery%3A+What+Four+Randomized+Trials+Did+Not+Establish%20https%3A%2F%2Fcedclinic.com%2Fliraglutide-cardiac-surgery-randomized-trials-meta-analysis%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Safety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.](https://pubmed.ncbi.nlm.nih.gov/42693519/) Related Reading at CED ClinicContinue exploring the evidence[GLP-1 Receptor Agonist Benefits in Cardiac Interventions](https://cedclinic.com/tirzepatide-perioperative-cardioprotective-effects-cardiac-care/) Earlier CED coverage of perioperative GLP-1 questions in cardiac care. [Compare earlier cardiac coverage](https://cedclinic.com/tirzepatide-perioperative-cardioprotective-effects-cardiac-care/)[GLP-1 Weight Loss Medicine: Surgical Risk Reduction](https://cedclinic.com/glp-1-weight-loss-surgical-risk-reduction/) Related discussion of surgical risk and the limits of observational inference. [Review surgical context](https://cedclinic.com/glp-1-weight-loss-surgical-risk-reduction/)[Medical Nutrition Therapy in Incretin-Treated Heart Failure](https://cedclinic.com/medical-nutrition-therapy-hfpef-incretin-framework/) Clinical context for nutrition and monitoring during incretin therapy. [Explore coordinated care](https://cedclinic.com/medical-nutrition-therapy-hfpef-incretin-framework/) ## Frequently Asked Questions What did the liraglutide review examine? It pooled randomized trials of perioperative subcutaneous liraglutide versus placebo or insulin-based usual care in adults undergoing cardiac surgery. How much evidence was included? Seven reports from four randomized trials included 446 randomized patients. Did liraglutide reduce 30-day mortality? No clear effect was established. Only four deaths were reported, and the confidence interval was very wide. Did liraglutide reduce postoperative complications? No statistically clear difference was found for the composite of any postoperative complication. Did liraglutide reduce cardiac adverse events? No statistically clear difference was reported for cardiac adverse events. Did liraglutide reduce hypoglycemia? No clear reduction was established; the confidence interval included meaningful benefit and harm. What did the review find about nausea and vomiting? The estimate was highly imprecise, ranging from possible reduction to a very large increase. Were glycemic efficacy results available? The accessible PubMed abstract did not report the glycemic estimates named in the title, and full text was unavailable. Should patients stop liraglutide before surgery? This meta-analysis does not make that decision. Patients need individualized instructions from their prescribing, surgical, anesthesia, and diabetes teams. What is the main evidence limitation? Only four small trials were available, event counts were low, and several pooled estimates were too imprecise for firm conclusions. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).